You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 357 GLS-010 (Zimberelimab), a novel fully human anti-PD-1 mAb in chinese patients with recurrent/metastatic cervical cancer: results from a multicenter, open-label, single-arm phase II trial

Citation Tools

Article menu

Download PDFPDF

Poster
IGCS20_1382
357 GLS-010 (Zimberelimab), a novel fully human anti-PD-1 mAb in chinese patients with recurrent/metastatic cervical cancer: results from a multicenter, open-label, single-arm phase II trial
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Wu X, Xia L, Zhou Q, et al
357 GLS-010 (Zimberelimab), a novel fully human anti-PD-1 mAb in chinese patients with recurrent/metastatic cervical cancer: results from a multicenter, open-label, single-arm phase II trial
International Journal of Gynecologic Cancer 2020;30:A147.